Introduction: From Laboratory to Clinical Reality

Transcranial photobiomodulation (tPBM) has emerged from promising laboratory research into demonstrable clinical applications. This comprehensive review examines the current evidence base, focusing on quantifiable outcomes across three critical domains: cognitive enhancement in healthy populations, neurodegenerative condition management, and sleep-mood regulation benefits.

PBM acts primarily through the activation of cytochrome c oxidase, a key mitochondrial enzyme. Nitric oxide plays a crucial role in mitochondrial function by modulating cytochrome c oxidase activity, and PBM can enhance nitric oxide signaling, thereby improving mitochondrial respiration and cellular health.

At the cellular level, PBM influences a variety of processes, including the regulation of calcium ions, which are essential for cell signaling, proliferation, and differentiation. PBM can also activate light sensitive ion channels at specific wavelengths, leading to increased calcium ion influx and modulation of neural activity.

Gene expression changes and stem cell differentiation are mediated in part by the activation of transcription factors through PBM, which leads to enhanced mitochondrial biogenesis, antioxidant activity, and tissue repair. In particular, PBM has been shown to promote the proliferation and differentiation of mesenchymal stem cells, supporting tissue regeneration.

The cellular mechanisms underlying PBM include a range of molecular mechanisms, such as the modulation of mitochondrial activity, regulation of cytokine production, and changes in gene expression.

In neurodegenerative diseases, mitochondrial dysfunction is a key pathological factor contributing to disease progression. PBM targets this dysfunction by supporting mitochondrial function, reducing oxidative stress, and promoting neuronal survival.

Inflammation is another critical area influenced by PBM. The therapy modulates the inflammatory response by regulating inflammatory mediators, such as cytokines and chemokines, which play a central role in tissue repair and immune regulation.

Light therapy parameters, including the application of light radiation at specific wavelengths (such as 810 nm and 905 nm), have significant effects on cellular processes like cytokine production, immune cell activity, and tissue regeneration.

Proper dosimetry is essential for effective PBM, with energy density and energy densities (measured in J/cm²) being key factors that determine biological outcomes and optimize treatment efficacy.

Device parameters, such as power output, are critical for ensuring both the safety and efficacy of PBM devices, as they influence therapeutic effects and minimize risks like tissue overheating.

Light sources used in PBM include red light and near infrared light, each with distinct roles: red light primarily activates mitochondrial pathways at shallower tissue depths, while near infrared light penetrates deeper and is effective in activating cytochrome c oxidase for enhanced ATP production.

LLLT can also be delivered using light emitting diode (LED) technology, which allows for multiwavelength applications and targeted treatment of cellular processes, including mitochondrial function and inflammation.

Visuel tPBM Neurons
Your Neurons Hold the Key to a Better Life

Human Cells and Brain Function: The Biological Foundation

Human cells are the building blocks of all tissues and organs, and their health is fundamental to optimal brain function. In the brain, billions of specialized cells called neurons work together to support cognitive processes such as perception, memory, attention, and decision-making. The intricate communication between these cells underpins everything from basic sensory input to complex thought and behavior.

Recent advances in low level laser therapy (LLLT) and photobiomodulation therapy (PBMT) have revealed how targeted light irradiation can influence the behavior of human cells, particularly in the context of brain injury and neurodegenerative diseases. LLLT, which utilizes low-intensity laser or light emitting diodes, has been shown to enhance cellular metabolism, accelerate wound healing, and promote tissue repair. For example, research using mouse embryonic fibroblasts has demonstrated that laser therapy can increase ATP production, reduce oxidative stress, and stimulate the healing process at the cellular level.

A key molecular mechanism behind these effects is the activation of cytochrome c oxidase, a crucial enzyme in the mitochondrial respiratory chain. When stimulated by laser irradiation, cytochrome c oxidase boosts the production of ATP, the primary energy currency of the cell. This increase in cellular energy supports a range of vital functions, from cell proliferation to the repair of damaged tissue. Additionally, LLLT can modulate the production of reactive oxygen species (ROS), which act as signaling molecules to trigger beneficial cellular processes involved in tissue regeneration and immune response.

Stem cells are another promising area of research in the field of brain function and tissue repair. These versatile cells have the unique ability to differentiate into various cell types, including neurons, making them essential for tissue regeneration following traumatic brain injury or in the context of neurodegenerative diseases. Studies have shown that low level light therapy can enhance the proliferation and differentiation of stem cells, in part by influencing stem cell epigenetic memory and gene expression. This means that laser treatment may help guide stem cells to become the specific cell types needed for brain repair and recovery.

Clinical trials and systematic reviews have begun to translate these cellular findings into real-world benefits. Photobiomodulation therapy has demonstrated significant improvements in cognitive function and cognitive performance, particularly in individuals with cognitive impairment or conditions such as Alzheimer’s disease. These therapies have also been associated with a significant reduction in inflammatory cytokines, supporting a healthier brain environment and potentially slowing the progression of neurodegenerative diseases.

In summary, the interaction between light therapy and human cells forms the biological foundation for many of the clinical benefits observed with PBMT and LLLT. By targeting cellular mechanisms such as cytochrome c oxidase activation, ATP production, and stem cell differentiation, these therapies offer new hope for tissue repair, wound healing, and the restoration of brain function after injury or in the face of chronic diseases. As research continues, a deeper understanding of these cellular processes will be essential for optimizing treatment protocols and expanding the therapeutic potential of photobiomodulation in neurology and beyond.

Click here to learn more about Optimal Brain Function using tPBM

Cognitive Enhancement in Healthy Individuals

Neuromuscular and Cognitive Performance

Johnson et al. (2024) conducted a proof-of-concept study with 43 participants (ages 18-69) who had histories of repetitive head acceleration events. Following 8 weeks of combined intranasal and transcranial PBM therapy using Vielight devices, significant improvements were documented:

  • Reaction Time: Effect size g = 0.75 (large effect). Substantial improvement in sensorimotor processing speed
  • Balance Control (MiniBEST): Effect size g = 0.63 (medium-large effect). Significant improvement in the ability to respond to balance disturbances
  • Grip Strength: g = 0.22 (dominant) and g = 0.34 (non-dominant hand). Improvement in peripheral strength, suggesting systemic effects of cerebral PBM

Creative Cognitive Enhancement

Default mode network WRNMMC
Magnetic resonance imaging of areas of the brain in the default mode network. (Graner et al. 2013)

Peña et al. (2024) demonstrated that transcranial photobiomodulation over the default mode network enhanced divergent creative thinking in healthy adults. The study showed significant improvements in:

  • Total Divergent Thinking (DT): Significant enhancement (p = 0.004, η² = 0.24)
  • Unusual Uses Test: Improved fluency and originality scores
  • Picture Completion Test: Enhanced performance metrics

The research utilized 810nm wavelength with precise dosimetry targeting the prefrontal cortex, demonstrating PBM’s capacity for cognitive enhancement beyond therapeutic applications.

Improvements in Dementia and Neurodegenerative Conditions

Alzheimer's Disease and Dementia

Saltmarche et al. (2017) published the first completed case series documenting significant cognitive improvements in mild to moderately severe dementia using Vielight Neuro devices. Key findings included:

  • ADAS-cog Scores: Sustained improvement throughout 12-week treatment period, with continued benefits during follow-up
  • Neuropsychiatric Inventory (NPI-FS): Significant behavioral improvements
  • Functional Independence: Enhanced activities of daily living
  • Safety Profile: Zero adverse events reported across all participants

Advanced Neuroimaging Validation

Chao (2019) conducted a randomized pilot trial demonstrating both clinical and neuroimaging evidence of PBM efficacy in dementia:

Clinical Outcomes:

  • ADAS-cog improvement: Statistically significant cognitive enhancement compared to usual care
  • Behavioral regulation: Measured via Neuropsychiatric Inventory improvements
  • Sustained benefits: Effects maintained through 24-week follow-up period

Neuroimaging Evidence:

  • Increased cerebral perfusion: Demonstrated via arterial spin labeling MRI
  • Enhanced connectivity: Functional connectivity improvements in default mode network
  • Structural preservation: Reduced atrophy progression compared to controls

Chronic Traumatic Encephalopathy (CTE)

Naeser et al. reported remarkable improvements in ex-football players with probable CTE symptoms following transcranial PBM therapy:

Cognitive Domains:

  • Executive function: Significant improvements in Stroop test performance
  • Memory enhancement: Verbal learning and memory improvements
  • Attention regulation: Sustained attention capacity increases

Behavioral/Mood Improvements:

  • PTSD symptoms: Significant reduction in PCL-C scores
  • Pain management: Decreased SF-MPQ pain ratings
  • Sleep quality: Improved PSQI scores

Systematic Review Evidence

A comprehensive systematic review (Lim, 2024) identified seven clinical studies in Alzheimer’s disease with consistent findings:

  • Universal safety profile: No adverse events reported across studies
  • Cognitive improvements: Consistent enhancements in memory and cognition domains
  • Heterogeneous parameters: Studies varied in wavelength (660-1070nm), power density, and treatment duration
  • Clinical significance: Effect sizes ranging from small to large across cognitive measures

Sleep Quality and Mood Regulation Benefits

Sleep Architecture Improvements

Zhao et al. (2022) conducted a randomized, sham-controlled study demonstrating significant sleep quality improvements in subjective cognitive decline:

  • Pittsburgh Sleep Quality Index (PSQI): Significant improvements compared to sham control
  • Sleep efficiency: Enhanced sleep architecture parameters
  • Subjective sleep quality: Patient-reported improvements in sleep satisfaction

Neurochemical Mechanisms

Research demonstrates PBM’s influence on sleep-related neurochemical pathways:

Circadian Regulation:

  • Enhanced melatonin production regulation
  • Improved circadian rhythm synchronization
  • Optimized sleep-wake cycle stability

Neurotransmitter Modulation:

  • Increased serotonin and dopamine availability
  • Enhanced GABA system function
  • Reduced cortisol and stress hormone levels

Mood and Stress Regulation

Multiple studies document mood enhancement effects:

Depression and Anxiety:

  • Significant improvements in Beck Depression Inventory scores
  • Reduced anxiety measures across multiple assessment scales
  • Enhanced emotional regulation capacity

Stress Response:

  • Improved heart rate variability
  • Reduced inflammatory markers (IL-6, TNF-α)
  • Enhanced stress resilience measures

Technical Parameters for Optimal Outcomes

Vielight Neuro Device Specifications

Light Parameters:

  • Wavelength: 810nm (Near-infrared)
  • Power Density: 100-300 mW/cm²
  • Pulse Frequency: 10Hz (Alpha) and 40Hz (Gamma) modes
  • Treatment Duration: 20 minutes per session
  • Dosimetry: 60 J/cm² scalp dose achieving 5-10 J/cm² neuronal dose

Evidence-Based Protocol Optimization

Research suggests optimal parameters include:

  • Frequency: 3 times per week minimum for sustained effects
  • Duration: 8-12 week initial treatment protocols
  • Maintenance: Ongoing sessions required for sustained benefits in neurodegenerative conditions
  • Individualization: Parameter adjustment based on EEG feedback and clinical response

Future Research Directions and Clinical Implications

Current Research Limitations

  • Sample sizes: Most studies involve small cohorts (4-57 participants)
  • Parameter heterogeneity: Variability in wavelength, dosing, and protocols
  • Standardization needs: Requirement for unified assessment measures
  • Long-term studies: Need for extended follow-up periods

Emerging Applications

EEG-Guided Protocols:

  • Real-time brain state monitoring for parameter optimization
  • Personalized frequency selection based on individual brain rhythms
  • AI-driven treatment customization

Combination Therapies:

  • Synergistic effects with neurofeedback training
  • Integration with cognitive behavioral interventions
  • Multimodal neuromodulation approaches

Clinical Implementation Considerations

Safety and Contraindications

Established Safety Profile:

  • No serious adverse events in published literature
  • Mild temporary effects: fatigue, headache, dry throat (typically resolve within 1-2 sessions)
  • Contraindications: Active brain bleeds, seizure history, pregnancy

Regulatory Status

Current Classification:

  • FDA categorized as “low-risk general wellness devices”
  • TÃœV safety certification for consumer use
  • Not approved for specific medical treatment claims
  • Clinical application requires appropriate informed consent and professional oversight

Bottom Line: Evidence-Based Implementation

The clinical evidence for transcranial photobiomodulation demonstrates consistent, measurable benefits across cognitive, behavioral, and neurophysiological domains. Key takeaways for clinical practice:

  1. Robust Safety Profile: Extensive research confirms minimal risk with proper protocols
  2. Measurable Efficacy: Effect sizes ranging from small to large across multiple outcome measures
  3. Broad Applications: Benefits demonstrated in both healthy enhancement and therapeutic contexts
  4. Technical Precision: Optimal outcomes require evidence-based parameter selection and dosimetry
  5. Professional Integration: Greatest benefits achieved within comprehensive neurotherapy frameworks

For Neurofeedback Luxembourg clients, tPBM represents a scientifically-validated addition to our neurotherapy suite, offering unique advantages in brain optimization and therapeutic intervention protocols.

This review synthesizes current peer-reviewed research through January 2025. Individual results may vary. Professional consultation recommended for therapeutic applications.

Discover your brain optimization potential today. Visit our website to learn more about photobiomodulation and our integrated approach, and schedule your preliminary teleconsultation. Together, let’s explore how transcranial photobiomodulation can transform your brain health.

References

Chao, L. L. (2019). Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia : A Pilot Trial. Photobiomodulation, Photomedicine, and Laser Surgery, 37(3), 133‑141. https://doi.org/10.1089/photob.2018.4555

Graner, J., Oakes, T. R., French, L. M., & Riedy, G. (2013). Functional MRI in the investigation of blast-related traumatic brain injury. Frontiers in neurology, 4, 16. https://doi.org/10.3389/fneur.2013.00016

Johnson, P. K., Fino, P. C., Wilde, E. A., Hovenden, E. S., Russell, H. A., Velez, C., Pelo, R., Morris, A. J., Kreter, N., Read, E. N., Keleher, F., Esopenko, C., Lindsey, H. M., Newsome, M. R., Thayn, D., McCabe, C., Mullen, C. M., Davidson, L. E., Liebel, S. W., … Tate, D. F. (2024). The Effect of Intranasal Plus Transcranial Photobiomodulation on Neuromuscular Control in Individuals with Repetitive Head Acceleration Events. Photobiomodulation, Photomedicine, and Laser Surgery, 42(6), 404‑413. https://doi.org/10.1089/pho.2023.0178

Lim, L. (2024). Modifying Alzheimer’s disease pathophysiology with photobiomodulation : Model, evidence, and future with EEG-guided intervention. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1407785

Naeser, M. A., Martin, P. I., Ho, M. D., Krengel, M. H., Bogdanova, Y., Knight, J. A., Hamblin, M. R., Fedoruk, A. E., Poole, L. G., Cheng, C., & Koo, B. (s. d.). Transcranial Photobiomodulation Treatment : Significant Improvements in Four Ex-Football Players with Possible Chronic Traumatic Encephalopathy. Journal of Alzheimer’s Disease Reports, 7(1), 77‑105. https://doi.org/10.3233/ADR-220022

Peña, J., Muthalib, M., Beaty, R. E., Sampedro, A., Ibarretxe-Bilbao, N., Zubiaurre-Elorza, L., García-Guerrero, M. A., Cortazar, I., Niso, M., & Ojeda, N. (2024). Enhancement of Divergent Creative Thinking After Transcranial Near-Infrared Photobiomodulation Over the Default Mode Network. Creativity Research Journal, 36(1), 1‑14. https://doi.org/10.1080/10400419.2023.2219953

Saltmarche, A. E., Naeser, M. A., Ho, K. F., Hamblin, M. R., & Lim, L. (2017). Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation : Case Series Report. Photomedicine and Laser Surgery, 35(8), 432‑441. https://doi.org/10.1089/pho.2016.4227

Zhao, C., Li, D., Kong, Y., Liu, H., Hu, Y., Niu, H., Jensen, O., Li, X., Liu, H., & Song, Y. (s. d.). Transcranial photobiomodulation enhances visual working memory capacity in humans. Science Advances, 8(48), eabq3211. https://doi.org/10.1126/sciadv.abq3211